An m5C methylation regulator-associated signature predicts prognosis and therapy response in pancreatic cancer

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is the most aggressive digestive malignancy due to frequent late-stage diagnosis, rapid progression and resistance to therapy. With increasing PDAC incidence worldwide, there is an urgent need for new prognostic biomarkers and therapy targets. Recently, RNA methylation has emerged as a new tumorigenic mechanism in different cancers. 5-methylcytosine (m5C) is one of the most...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Epigenetics and DNA Methylation
• Share to Pancreatic and Hepatic Oncology Research
• Share to RNA modifications and cancer